<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04613960</url>
  </required_header>
  <id_info>
    <org_study_id>MTH/NEUR/20/01</org_study_id>
    <nct_id>NCT04613960</nct_id>
  </id_info>
  <brief_title>Magnesium Treating Subarachnoid Hemorrhage Vasospasm</brief_title>
  <acronym>MATSH-SHapE</acronym>
  <official_title>Magnesium in Treating Subarachnoid Hemorrhage Related Vasospasm, A Haptoglobin Genomic Based Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>General Committee of Teaching Hospitals and Institutes, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ain Shams University, Faculty of medicine, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Health Insurance Organization, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>General Committee of Teaching Hospitals and Institutes, Egypt</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial investigating magnesium sulphate ability to reduce risk of&#xD;
      cerebral vasospasm after acute subarachnoid hemorrhage hence improving outcome particularly&#xD;
      in haptoglobin 2-2 patients who are highly susceptible for severe complications after&#xD;
      subarachnoid hemorrhage.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design and Location:&#xD;
&#xD;
      Investigators propose a double blinded, randomized (1:1), placebo-controlled, multicenter,&#xD;
      clinical trial including patients with acute aSAH. Participants will be allocated either to&#xD;
      MgSO4 or placebo. The permission to conduct the study protocol will be considered for&#xD;
      approval by the ethics committee of General Committee of Teaching Hospitals and Institutes&#xD;
      (GCTHI), Egypt. The study will be conducted in 3 centers; El-Materia Educational Hospital,&#xD;
      Ain Shams University Hospitals and Nasr City Insurance Hospital. The assigned centers for&#xD;
      this study represent large-volume referral stroke centers that provide comprehensive&#xD;
      management protocols for aSAH.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical evidence and TCD measured MFV indicative of vasospasm</measure>
    <time_frame>14 days after onset</time_frame>
    <description>Mean flow velocity measurements by TCD indicative of cerebral vasospasm. New clinical neurological deficit determined by comparing NIHSS pre and post detected vasospasm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Poor MRS functional score</measure>
    <time_frame>3 months after the onset</time_frame>
    <description>Poor MRS score (4,5 or dead) assessed at regular follow up visits</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Subarachnoid Hemorrhage, Aneurysmal</condition>
  <condition>Cerebral Vasospasm</condition>
  <arm_group>
    <arm_group_label>Magnesium arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients randomized to magnesium therapy at a fixed daily dose of 64 mmol reconstituted in 0.9% saline via continuous intravenous infusion for 14 days after hemorrhage onset, or until discharge or death if it occurred.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>patients randomized to placebo therapy with 0.9% saline (without active component) via same protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium sulfate</intervention_name>
    <description>MgSO4 (at a fixed daily dose of 64 mmol reconstituted in 0.9% saline) via continuous intravenous infusion for 14 days after onset</description>
    <arm_group_label>Magnesium arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>normal saline</intervention_name>
    <description>Placebo treatment</description>
    <arm_group_label>Placebo arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of both genders&#xD;
&#xD;
          -  age over 18 years old&#xD;
&#xD;
          -  diagnosis of acute aSAH (â‰¤ 48 hours) confirmed with angiographic evidence of cerebral&#xD;
             aneurysm and CT brain on admission.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  subarachnoid hemorrhage due to non-aneurysmal causes&#xD;
&#xD;
          -  cerebral stroke of any type during past month&#xD;
&#xD;
          -  decompensated heart failure, renal failure or hepatic failure&#xD;
&#xD;
          -  difficult bilateral transtemporal transcranial Doppler (TCD) insonation of&#xD;
             intracranial arteries due to thick temporal bone of the skull.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed M Ateia</last_name>
    <phone>+201202474777</phone>
    <email>a_ateia@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>El matareya Educational Hospital</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmed M Ateia</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Reddy D, Fallah A, Petropoulos JA, Farrokhyar F, Macdonald RL, Jichici D. Prophylactic magnesium sulfate for aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. Neurocrit Care. 2014 Oct;21(2):356-64. doi: 10.1007/s12028-014-9964-0. Review.</citation>
    <PMID>24619389</PMID>
  </reference>
  <reference>
    <citation>Soliman R, Zohry G. [Effect of magnesium sulphate and milrinone on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a randomized study]. Braz J Anesthesiol. 2019 Jan - Feb;69(1):64-71. doi: 10.1016/j.bjan.2018.09.005. Epub 2018 Nov 6. Portuguese.</citation>
    <PMID>30409409</PMID>
  </reference>
  <reference>
    <citation>Thomsen JH, Etzerodt A, Svendsen P, Moestrup SK. The haptoglobin-CD163-heme oxygenase-1 pathway for hemoglobin scavenging. Oxid Med Cell Longev. 2013;2013:523652. doi: 10.1155/2013/523652. Epub 2013 May 27. Review.</citation>
    <PMID>23781295</PMID>
  </reference>
  <reference>
    <citation>Milman U, Blum S, Shapira C, Aronson D, Miller-Lotan R, Anbinder Y, Alshiek J, Bennett L, Kostenko M, Landau M, Keidar S, Levy Y, Khemlin A, Radan A, Levy AP. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol. 2008 Feb;28(2):341-7. Epub 2007 Nov 21.</citation>
    <PMID>18032779</PMID>
  </reference>
  <results_reference>
    <citation>Ateia AM, Elbassiouny A, El-Nabi SH, Fahmy NA, Ibrahim MH, El-Garawani I, Geba KM, Khalaf M. Predictive value of haptoglobin genotype as a risk of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg. 2020 Dec;199:106296. doi: 10.1016/j.clineuro.2020.106296. Epub 2020 Oct 7.</citation>
    <PMID>33069930</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 3, 2020</study_first_posted>
  <last_update_submitted>July 1, 2021</last_update_submitted>
  <last_update_submitted_qc>July 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General Committee of Teaching Hospitals and Institutes, Egypt</investigator_affiliation>
    <investigator_full_name>Ahmed Mohammed Ateia</investigator_full_name>
    <investigator_title>Neurology Specialist, MTH; Associate member, Harvard Medical School.</investigator_title>
  </responsible_party>
  <keyword>subarachnoid hemorrhage</keyword>
  <keyword>Haptoglobin</keyword>
  <keyword>Vasospasm</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Vasospasm, Intracranial</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>all IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>starting 6 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

